Sitemap
Pages
- Blogs
- Policies
- Videos
- Sitemap
- Biomedical Waste Returns
- Discovery Biology
- Policies
- Financial Statements of Subsidiaries
- Corporate Governance
- Board Committees
- Information, Reports, Notices etc.
- Credit Ratings
- Annual Returns
- Notices of meetings of the board for financial results
- Investor Greivances Redressal
- Debenture Trustee Details
- Annual Reports
- Financial Results
- Disclosures under Regulation 62 of the LODR
- The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
- Training Calendar
- Cell Line Development
- Virtual Site
Tour - Our Responsibility
- Utlities
- Contact Us
- Contact Us
- ThankYou
- ThankYou
- Careers
- Aragen Life Sciences is a trusted R&D and manufacturing partner to the global life sciences industry
- Our Company
Posts by category
- Category: Uncategorized
- What is Pharmaceutical Formulation Development?
- What are the Roles of Genomics and Proteomics in Drug Discovery and Personalized Medicine?
- What is Structural Biology?
- What is Medicinal Chemistry in Drug Discovery?
- The Role of Green Chemistry in Driving Success in Chemical Innovations
- Optimizing Pharmaceutical Processes and Enhancing Biological Experimental Design Efficiency with Design of Experiments Methodology
- The Essential Role of Analytical Chemistry in the Pharmaceutical Industry
- Overcoming Challenges in Chemical Engineering during Pharmaceutical Scale-Up
- What is Lead Identification in Drug Discovery?
- What is High-Throughput Screening in Drug Discovery
- What is Biologics Development?
- Innovative Solutions: Overcoming Chemical Synthesis Hurdles in the Global CDMO Landscape
- Navigating Growth: Challenges and Opportunities in the Small Molecule CDMO Sector
- The Synergy of Services: How CDMOs Drive Innovation in Medicinal Chemistry?
- CDMOs: Pioneering Partnerships in Immuno-Oncology Drug Development
- What are Performance Chemicals?
- What is Molecular Biology?
- Streamlining Small Molecule Drug Development: The Advantages of Integrated CDMOs
- Maximizing Efficiency: How High-Throughput Screening Services Drive Drug Discovery
- The Rise of High Potent APIs: Trends, Technologies, and Manufacturing Best Practices
- CDMO Innovations: Advancing Pharma Manufacturing with Chemical Development Solutions From Early To Late Phase
My Templates
Solutions
- Small Molecules
- Discovery
- Integrated Drug Discovery
- Chemistry
- Medicinal Chemistry
- Peptide Platform
- Synthetic Chemistry
- Specialty Chemistry
- Analytical Chemistry
- Oligonucleotide
- Biology
- Reagent Generation
- Molecular Biology
- Protein Expression Screening & Scale Up
- Protein Purification
- Protein Characterization
- Cell Line Generation
- In Vitro Pharmacology
- DMPK
- In Vivo Pharmacology
- Safety Pharmacology
- Protein Sciences
- Safety Assessment
- Development & Manufacturing
- Drug Substance
- Performance Chemicals
- Drug Substance
- Process Research & Development
- Custom Manufacturing
- Drug Product
- Preformulation
- Toxicology Formulation
- Clinical Formulation
- Analytical Development
- Method Development & Validation
- Stability Studies
- Extractable & Leachable Studies
- Performance Chemicals
- Process Research & Development
- Custom Manufacturing
- Custom Chemical Synthesis
- Commercial Manufacturing
- Large Molecules
- Discovery
- Biology
- Toxicology
- In Vitro Pharmacology
- In Vitro & Ex Vivo Fibrosis Assays
- In Vivo Pharmacology
- Clinical Pathology/Histopathology
- Vivarium
- Fibrosis
- Oncology
- Immunology & Inflammation
- Infectious Disease Models
- Respiratory Disease Models
- Pain
- Cardio Vascular and Metabolic Diseases
- Other Models
- Pharmacokinetics (PK)
- Integrated Discovery
- Molecular Biology
- Antibody Discovery
- Hybridoma Development & Screening
- Antibody Production & Characterization
- Protein Sciences
- Protein Expression & Purification
- Protein Analytics
- Cell Line Development
- Therapeutics
- Diagnostics
- Research Reagents
- Development & Manufacturing
- Process Research & Development
- Bioproduction
- Developability & Analytics
- GMP Manufacturing
News
- Automation accelerators in drug discovery and development
- IRA matches BIOSECURE in driving CDMO sector in India
- Navigating the future: building a de-risked supply chain
- Biotech Industry's Path Towards Sustainability
- Indian CDMOs form trade group
- Algorithms to Treatments: AI’s Impact on Modern Drug Discovery
- Biologics Roundtable: The Current Landscape and Future Developments
- Indian drug services companies unite
- Clients add pressure to CDMOs to source raw materials outside of China, execs say
- Developing capabilities to profile the next gen compounds in new modalities is expected to drive preclinical CRO growth
- CDMO strategies for disrupting the biomanufacturing scale-up paradigm
- DevsHealth announces strategic partnership with Aragen for the chemical synthesis of its projects
- Enhancing Supply Chain Flexibility and Resilience
- Aragen Life Sciences receives Science Based Targets initiative (SBTi) approval for its greenhouse gas emission reduction targets
- India seeks a seat at the drug services table
- Expert View: Understanding the India CDMO Market
- Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services
- CDMO trends post-Wuxi’s exit from the US: who will take its place?
- The Discovery and Patent Acquisition of a New Hair Growth Substance
- CII Telangana CEO’s Round Table on Policy and Advocacy Discussion on Pharma Service
- Biosecurity threats and business as usual
- Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
- Aragen Bioscience Validates Getinge's Single-Use Production Reactor (SUPR)
- Home and US CAPEX places India on brink of bioCDMO breakthrough
- "Automation is critical to improve operational efficiency and accelerate innovation" - Subodh Deshmukh and Ramesh Subramanian
- Aragen’s Formulation Manufacturing Facility Achieves GMP Certification from Telangana Drugs Control Administration
- Aragen's Validation Journey with Getinge's SUPR Single-Use Bioreactors
- Contract Manufacturing: Pharma’s New Growth Pill
- Indian CDMOs expand capacities: Syngene and Aragen lead the way
- Biopharma manufacturing ‘turbulence’ boosts inquiries for India-based providers, local CDMO execs say
- Aragen operationalizes first phase of its Biologics manufacturing facility in India
- DHL Express India and Aragen LifeSciences sign GoGreen Plus partnership to reduce carbon emissions
- Aragen Life Sciences expands its operations from Hyderabad
- Ramesh Subramanian shares insights with LSKH – Life Sciences Knowledge Hub
- Innovations in Pharmaceutical R&D: Navigating the Future.
- Indian drug manufacturers benefit from Big Pharma interest beyond China
- Beyond Manufacturing: Broadening Horizons of CDMOs
- "We expect biologics manufacturing to be a major area of contract services growth in the next 2-3 years."- Ramesh Subramanian on Aragen's upcoming biologics manufacturing facility
- Targeted Protein Degraders - The druggability perspective
- Heard at #CPHI: VC funding trends; Samsung eyes expansion; and supply chain diversification
- Aragen setting up a $ 30 million bio-manufacturing site in India
- Aragen Commissions a state-of-the-art Formulations Manufacturing Facility in Hyderabad, India
- Driving Dosage Form Developments
- We propose an export zone for project approvals from the government, enabling rapid manufacture of chemicals and products for global companies
- Forging robust partnerships in biologics development
- FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration
- Long-acting injectables for biologics: Current landscape and future perspective
- Aragen expands collaboration with Blueprint Medicines
- Manni Kantipudi & Ramesh Subramanian
Chief Executive Officer (MK) & Chief Commercial Officer (RS), Aragen Life Sciences - Best practices & strategies for biotherapeutics production using a stable scale-up process
- Aragen continues to ride CDMO growth wave as CEO honoured at CPHI Awards
- CSIR-IICT, Aragen and Kewaunee sign MOU for offering “Finishing School” skill program to postgraduate students in Chemistry
- CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences
- Predicting Pharma’s Future
- Automation accelerators in drug discovery and development
- China’s challenge in the drug services field
- Aragen sets it sights on biologics manufacturing with India facility
- Cell line platform reduces timelines by 33%, says Aragen
- Aragen launches royalty-free CHO GS cell line development platform under RapTr2022
- Aragen to operationalize cutting-edge formulation manufacturing facility in Hyderabad, India
- Aragen extends collaboration with NeoVac
- Aragen Life Sciences: Strengthening A Positive Work Culture Through Employee Empowerment
- V Madhusudan, CEO - Projects, TSIIC Limited and Manni Kantipudi, CEO, Aragen Life Sciences lay foundation stone for minor bridge and VRCC Stormwater drain at Mallapur
- Aragen expands collaboration with MSD to provide discovery services to support MSD’s global R&D
- Targeted Protein Degradation: Challenges And Opportunities
- Challenges In Developing Effective Therapeutics Against Respiratory Syncytial Virus Infection
- Analytical Prowess Powers Efficient CLD Through Data-Driven Decision-Making
- Manni Kantipudi (Chief Executive Officer) & Ramesh Subramanian (Chief Commercial Officer), Aragen Life Sciences, in an exclusive interview with GBR
- India’s One-Stop Shops
- Responsible Growth
- Electron mobility with photoredox catalysis
- Employer Branding: Imperative for talent attraction and retention
- Aragen Life Sciences donates ambulance to Government of Telangana
- Aragen receives Great Place to Work certification for the 3rd consecutive year
- Balancing Internal Focus Against External Capabilities
- Integrated CDMO Growth Will Lead to Patients Seeing Record Number of Drugs Making it to Market
- Testing Cell Line Development Technology Platforms In Parallel
- Why this company focuses on employee branding to retain top notch talent
- CDMO industry to see increasing consolidation both in global and Indian markets: Manni Kantipudi
- Developments and Discovery in Modern Drug Research
- Aragen acquires Intox Pvt. Ltd.
- "Business Growth Is Directly Proportional To Employee Satisfaction"
- Aragen focuses on securing biologics capacity within ‘competitive’ CDMO space
- Aragen expects to ride wave of US biotech growth in 2022
- Career in Life Sciences – Outlook and opportunities
- Branding CROs/CDMOs: Aragen, a case in point
- Post pandemic future for CROs and CDMOs in India
- Goldman Sachs-backed Aragen Life Sciences on expansion mode, evaluating select acquisition opportunities
- “R&D outsourcing has become a ‘must have’ than ‘good-to have’ strategy”
- Hyderabad-based Aragen accelerating drug, vaccine development
- Hyderabad-based Aragen to expand footprint in US
- Aragen: A Collaborative Initiative To Improve Human Lives
- Big ambitions for India’s contract research firms
- GBR: Interview with Manni Kantipudi, CEO and Ramesh Subramanian, CCO Aragen Life Sciences
- Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"
- Ramesh Subramanian, Chief Commercial Officer at Aragen speaks about “CDMO deal-making in a pandemic and beyond” at CPhI North America
- Manni Kantipudi, CEO, Aragen Life Sciences speaks in-depth about the company’s brand story and value differentiators in this interview with Pharma Focus Asia
- Aragen Announces Partnership with Skyhawk Therapeutics, Aimed at Developing Novel Small Molecule Therapeutics that Correct RNA Expression.
- Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim
- Covid – 19 vaccination drive for employees in Mallapur Industrial Area Local Authority (IALA) community
- Aragen announce multi-year partnership with FMC Corporation, aims at accelerating Agro-chemical pipeline
- GBR: Interview with Manni Kantipudi, CEO and Ramesh Subramanian, CCO Aragen Life Sciences
- Aragen (Formerly GVK BIO) To Partner With Global Biopharma With a Renewed Brand Promise
- ETHealthworld: Interview with Ramesh Subramanian,
Chief Commercial Officer, Aragen - Goldman Sachs Invests in Aragen Life Sciences
- On Demand Webinar:Targeted Protein Degradation in Inflammation and Cancer Therapy
- Pharma Bio: Interview with Dr Somesh Sharma
- Celerity™ Supply Chain Tribe: Interview with Chandan Shirbhayye
- Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
- Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate the Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate
- Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process
- Aragen Bioscience and University of Technology, Sydney Enter MoU to Support and Accelerate Biologics R&D in Australia
- Aragen Bioscience Announces the Appointment of Steven Lang, PhD, MBA as Vice President, Biologics
- Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development
- GVK BIO Announces the Promotion of Sudhir Kumar Singh to Chief Operating Officer and the Appointment of Ramesh Subramanian as its New Chief Commercial Officer
- Drug Discovery: In Drug Discovery, it’s About Time
- Biological E and GVK BIO Announce Strategic R&D Partnership
- GVK BIO Announces the Appointment of Robert R. Ruffolo, PhD, to its Board of Directors
- GVK BIO Announces USFDA Approval for its cGMP Analytical Services Laboratory
- Telangana Today: GVK BIO Eyes Expansion - Targets Europe, US and China; Completes Inspection at its lab in Mallapur in Hyderabad
- LifeArc and GVK BIO Celebrate a Decade Of Partnership, Transforming Research Into Life-Saving Medicines
- GVK BIO Announces the Appointment of Axel Schleyer, PhD as Chief Executive Officer, Aragen Bioscience, Inc.
- GVK BIO Certified as an Authorized Economic Operator by CBIC
- GVK BIO Receives Second Runner Up Award at YES Bank’s Natural Capital Awards 2018
- Aragen Bioscience Expands RapTr Cell Line Development Services
- GVK BIO declared the 1st Runner-Up under the Innovation and Technology Category
- Aragen Bioscience Announces AAALAC Accreditation
- GVK Biosciences Completes 10 years in Collaboration with Nuevolution
- Telangana Today: GVK BIO Ramping up Operations
- GVK Biosciences Launches eCule, India’s First Mobile App for Drug Discovery solutions
- CFI.co: GVK Biosciences: Pushing the Envelope
- GVK BIO Launches Mobile App
- Business Trends: Delivering Research for Global Life Science Industry
- CFI.co Meets the CEO of GVK Biosciences: Manni Kantipudi
- Global Business Reports: GVK Recently Constructed Mumbai’s Much Acclaimed New Airport
- GVK Biosciences Receives Best Life Sciences QHSE Leadership India 2017
- GVK Biosciences Inaugurates a Process Engineering & Safety Evaluation Lab
- Project Ascent Goes Live
- RapTr Cell Line Development Services Introduced
- GVK BIO Stamps its Presence at the BIO International Convention
- GVK Biosciences Announces the Launch of a GMP-compliant Analytical Services Laboratory
- Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology
- GVK Biosciences Renews AAALAC International Accreditation in Animal Care
- GVK Biosciences Awarded Confederation of Indian Industry EHS Excellence Award 2016
- Aragen Bioscience Announces the Appointment of President
- GVK BIO wins the Global CSR Excellence & Leadership Awards
- Dow AgroSciences wins the Agrow Awards for Best Industry Collaboration with GVK Biosciences
- Increased Focus within Medivir’s R&D and Optimizing Resources Through a Partnership with GVK BIO
- Akaal Pharma, Australia Extends Collaboration with GVK BIO for Formulations Development Services to Support Phase II Clinical studies for the Topical Treatment of Psoriasis
- GVK Biosciences Strengthens its Tie-up with CTC Life Science Corporation, Japan
- GVK Biosciences Donates Rs. 20 Lakh to the Andhra Pradesh Chief Minister’s Relief Fund, Towards Cyclone Hudhud Relief Efforts
- GVK Biosciences Announces the Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
- NanoHealth (ISB Alumni Venture) Partners with GVK Biosciences for the use of GVK BIO’s Proprietary HEART platform
- GVK Biosciences and Aragen Bioscience Sign Definitive Agreement to Acquire Aragen Bioscience, Inc.
- GVK Biosciences and USFDA Announce Drug Repositioning Collaboration – License to GVK BIO SAR Database GOSTAR
- Drug Discovery Unit (DDU), University of Dundee Licenses GVK Biosciences’ Online SAR Database, GOSTAR
- GVK Biosciences Announces New Distributor in Taiwan
- USFDA Extends the License of the GVK BIO Biomarker Database
- GVK Biosciences Enters Into Research Collaboration with Endo Pharmaceuticals
- GVK Biosciences and Onconova Therapeutics Establish a Novel Joint Development Partnership to Advance New Drugs for Cancer
- GVK BIO Establishes the Largest Isotope Labeling Facility in India
- GVK Biosciences Licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute
- BioAsia 2012 from February 09; GVK Biosciences is Co-Industry Host
- GVK BIO Announces Multi-year Drug Discovery Collaboration
- GVK Biosciences Presented the Frost & Sullivan Growth Leadership Award in the Contract Research Service Market
- GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization
- GVK Biosciences Extends the License of its SAR Databases to Astellas Pharma
- Indiana CTSI Partners with GVK Biosciences to Provide National Access to Biomarker Database
- GVK Biosciences is the Preferred Provider to Global Health Product Development Partners Consortium to Focus on Drugs and Vaccines for Neglected Infectious Diseases
- GVK Biosciences Extends License of its Biomarker Database to the USFDA
- Asian Biotech Award for GVK Biosciences Chief
- Dow AgroSciences Identifies Lead Molecule in Collaboration with GVK Biosciences
- GVK Biosciences Receives AAALAC Accreditation for its Animal Facility
- GVK Biosciences Appoints Dr John Ellingboe as Senior Vice President, Discovery Chemistry
- Asia Life Science Services Resource Guide 2010: Contract Research in India – Cost, Developmental and Regulatory Issues
- Bayer Crop Science Signs Agreement with GVK Biosciences on Early-Stage Research Projects
- GVK Biosciences is the Winner of the European Outsourcing Award 2009 for Best New Partnership along with Wyeth Research
- GVK Biosciences and Quantitative Solutions Collaborate on Clinical Trial Outcome Databases
- GVK Biosciences Announces Appointment of Gerhard N Mayr to its Board of Directors
- GVK Biosciences Organizes Workshop on Clinical Trials
- GVK Biosciences Announces Agreement With University of Tokyo on GPCR Database
- GVK Biosciences Responds to DCGI’s Letter on Clinical Trial of Wyeth’s Investigational Vaccine
- GVK Biosciences and Crelux set up Fragment-Based Drug Discovery Platform to Deliver Lead Molecules
- Harvard Professor Tarun Khanna to Join GVK BIO Board
- GVK BIO Enters Into Drug Discovery Pact with Wyeth Pharmaceuticals
- GVK Biosciences Licenses its Toxicity Database to AstraZeneca
Events
- 8th Antifibrotic Drug Development Summit
- Festival of Biologics 2024
- Society for Immunotherapy of Cancer (SITC)
- World Vaccine Congress Europe 2024
- AgrochemEx
- ACT 2024 Annual meeting
- CPhI World Wide 2024
- Drug Delivery & Formulation
- EUROTOX 2024
- EFMC-ISMC 2024
- 8th Annual IPF Summit
- The Bioprocessing Summit 2024
- 4th Induced Proximity Summit
- Extractables & Leachables USA Smither
- 38th ACS National Medicinal Chemistry Symposium
- BOS Basel 2024
- 17thWRIB
- BIO International
- PEGS Boston Summit
- BVS & EMD Serono Research & Development Institute
- AAPS National Biotechnology Conference 2024
- Biotrinity
- Swiss Biotech Day
- Generis | American Biomanufacturing Summit
- EFMC-ACSMEDI Medicinal Chemistry Frontiers 2024
- Drug Discovery Chemistry
- World Vaccine Congress
- DCAT Week
- 4th Targeted Protein Degradation Summit Europe
- BioAsia 2024
- International Crop-Science Conference & Exhibition
- 23rd Annual PepTalk
- 42nd Annual J.P. Morgan Healthcare Conference
- 24th China International Agrochemical & Crop Protection Exhibition
- SOT/Tox Expo
- Antibody engineering & Therapeutics
- 7th AFDD Summit
- BOS Manchester
- 6th TPD Summit
- CPHI Barcelona
- AAPS PharmSci 360
- Festival of Biologics
- EUROTOX 2023
- IPF Summit
- 17th WRIB
- Discovery Europe 2023
- BOS Basel 2023
- CAC 2023
- BioTrinity
- Live webinar - The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
- BIO International
- 12th Drug Discovery Summit
- DCAT
- SOT/Tox Expo
- Targeted Protein Degradation
- TGF-β for immuno-oncology Drug Development Summit
- PEGS Boston Summit
- CPHI North America
- Bio Asia 2023
- BioSeed 2023
- 11th Drug Discovery Strategic Summit
- 10th Drug Discovery Strategic Summit
- Bio-on-The Rocks
- Proventa - Medicinal Chemistry Strategy Meetings
- Proventa - CMC Strategy Meeting
- Live webinar - Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
- 12th DDF Summit
- ISSX/MDO 2022 Meeting
- EFMC-ISMC
International Symposium on Medicinal Chemistry - Pharma Outsourcing
- 6th AFDD Summit
- 5th TPD Summit
- Discovery on Target
- 6th IPF Summit
- Live Webinar - Development of Covalent Drugs with New Emerging Technologies
- CPHI Frankfurt
- 16th WRIB (Workshops on Recent Issues in Bioanalysis)
- Bio International
- CPhI North America
- 9th Drug Discovery Strategic Summit
- BOS Basel 2022
- PEGS Boston Summit
- Bio on the Rocks
- Swiss Biotech Day 2022
- Live webinar - Accelerating Biologics Development to Medicines: Key Drivers of Success
- 2nd Annual TPD Europe
- BIO ASIA 2022
Future Ready - DCAT Week
- Bio on the Rocks
- 5th Annual Antifibrotic Drug Development Summit (AFDD)
- CII Life Sciences Conclave 2021
- Live webinar - Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions
- Antibody Engineering & Therapeutics 2021
- BioProcess Intl (BPI East) 2021
- Bioprocessing Summit 2021
- CPhI North America 2021
- 5th NASH Drug Development Summit
- 4th Targeted Protein Degradation Summit
- 5th Annual IPF Summit
- EFMC-ISMC 2021
- BIO Digital International Convention 2021
- BioAsia 2021
- 4th Annual NASH Summit
- Live Webinar–Targeted Protein Degradation in Inflammation and Cancer Therapy
- 3rd Annual Targeted Protein Degradation Summit
- CPhI Festival of Pharma
- 18th Annual Discovery On Target
- EFMC-ISMC Virtual Event 2020
- PEGS BOSTON
- 4th Annual IPF Summit 2020
- Cambridge Healthtech Institute’s 15th Annual Drug Discovery Chemistry
- Nitrosamine Impurities Forum Americas
- BIO 2020
- Bio International Convention (Digital) 2020
- BioAsia 2020
- 8th International Translational Cancer Research Conference
- 38th Annual J.P. Morgan Healthcare Conference
- Formulation Development & Drug Delivery (FDD) Conclave 2019
- CPhI Worldwide 2019
- BIO On The Rocks
- SSX INDIA 2019
- Discovery on Target
- Pharma Analytical Conclave 2019
- ISSX 2019
- CPhI China 2019
- BIO 2019
- DCAT Week
- BioAsia 2019
- AAPS 2018
- CPhI Worldwide 2018
- BIO 2018
- BIO Korea
- AusBiotech
- BioPharm AmericaTM
- ChemOutsourcing
- BASEL LIFE MipTec
- Pharmalytica
- RICT 2017
- in-PHARMA JAPAN 2017
- Bio Taiwan 2017
- EFMC-ISMC
- 18th Annual Oxford Global Drug Discovery Summit
- BIO (US)
- ChemSpec India
- CPhI Japan
- CPhI Worldwide 2021
Awards
- First CRDMO to receive approval for near-term and net-zero targets from the Science Based Targets initiative (SBTi) in India
- Aragen receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan
- Aragen has been honoured with the Excellence in Supplier Relationship Management Award at the ET Now Supply Chain Summit 2024 in New Delhi
- Best Organization in L&D Practices in the Pharma Sector award by Indian Society of Training & Development
- Aragen receives Great Place to Work certification for the 5th consecutive year
- Proud to be ranked amongst the best workplaces in the Pharmaceutical, Healthcare, and Biotech industries in 2023
- Aragen recognised as winner in two categories, "Excellence in supply chain innovation" and "Creativity and sustainable supply chain leadership" at 2nd BW supply chain competitiveness awards 2023
- Aragen receives Silver rating from EcoVadis for its sustainability initiatives
- Aragen wins Best Supply Chain Award in Contract Research Organization 2023 at 9th India Supply Chain & Logistics organized by ISCM
- We are delighted to be listed as "ESG Warriors of India" in the ESG Champions of India report released by Dun & Bradstreet
- Aragen's manufacturing facility at Visakhapatnam wins International Safety Award from the British Safety Council under Merit Category
- Aragen receives Great Place to Work certification for the 4th consecutive year.
- Recognized as the 'Most Preferred Workplace for the year 2022-23 among Health and Wellness firms' presented by Marksmen Daily
- Aragen Supply Chain Management (SCM) team has won the Digital Transformation Award at the Procurement Success Summit (PSS), held in Shanghai, China.
- Mr. Manni Kantipudi Recognised as the ‘CEO of the Year 2022’ at CPHI Frankfurt, Germany.
- Aragen has received Silver rating in recognition of our sustainability initiatives from EcoVadis.
- Aragen has received the “Top Organizations with Best Workplace Practices” award from the Asia Pacific HRM Congress.
- Manufacturing Unit II received Green leaf platinum award by Apex India Foundation
- Aragen is proud winner of "Best-in-class Supply Chain Sustainability Award" at the 14th Express Logistics and Supply Chain Leadership Awards.
- Aragen's manufacturing facility at Visakhapatnam wins 3rd consecutive International Safety Award from the British Safety Council; 2nd time under Merit Category
- Visakhapatnam manufacturing facility gets "GreenCo Silver" rating under the CII - Sohrabji Godrej Green Business Centre’s ‘Green Company Rating System’
- Aragen recognized amongst Top 5 India's Best Workplace in Biotechnology and Pharmaceuticals by Great Place to Work institute for the 2nd consecutive year.
- Visakhapatnam manufacturing unit: Silver award for commitment to EHS practices and best EHS innovation
- Mallapur campus, Hyderabad: Silver award for commitment to EHS practices; sectoral topper in R&D
- Bangalore campus: Bronze award for commitment to EHS practices
- Manufacturing Unit II received award under gold category and sectorial topper at CII Southern EHS excellence awards
- Bengaluru facility received silver award from CII SR EHS Excellence Awards 2022 its commitment to EHS practices
- Mallapur facility received gold award from CII SR EHS Excellence Awards 2022 for its commitment to excellence on EHS practices and sectoral topper award in R&D sector
- Aragen has received Global CSR Excellence & Leadership award for the category "Most Innovative COVID-19 Response" at the World CSR congress.
- Aragen has been recognized as National Best Employer Brand Award for 2021 by World HRD Congress.
- Aragen has been conferred the 'Most Promising Outsourcing Pharma Company 2022' award at the 20th global edition of the Business Leader of the Year awards, co-partnered by ETNow and CNBCTV18.
- We are delighted to share that Manni Kantipudi, CEO, Aragen Life Sciences, has been conferred the ‘CEO of the Year 2022 award’ at the 20th global edition of the Business Leader of the Year awards, co-partnered by ETNow and CNBC TV18.
- Aragen’s Unit II in Visakhapatnam manufacturing facility has won the Gold Award in the Best Industrial Safety Practices and digital initiatives categories at the Industrial Safety Excellence Awards 2022.
- Aragen’s MLR-3 facility in Mallapur, Hyderabad has received the ‘Best Project – Corporate’ award from The Infrastructure, Facility, Human Resource & Realty Association (iNFHRA).
- Aragen receives Great Place to Work certification for the 3rd consecutive year.
- Manufacturing Unit -I, Hyderabad received award under silver category at CII Southern EHS excellence awards-2022 - Jan 22
- Aragen has been awarded as winners for Supply chain strategy and design of the year at 10th Manufacturing Supply Chain Summit
- Aragen has been awarded a Bronze Medal in recognition of Global Sustainability Assessment 2021 by Ecovadis.
- Ranked 2nd Best Places to Work in India 2021 under Mid-Sized Pharma Company Category - by AmbitionBox
- Aragen is now among the top Best Workplaces in Biotechnology and Pharmaceutical industry 2021
- In recognition of our commitment to COVID-19 safety, awarded by Alden Global Value Advisors
- Aragen is certified for the second consecutive year, for a High-Trust, High-Performance Culture™, placing us among ‘Companies with the Best Culture’ for 2021-22
- In recognition of our commitment to keeping our workers healthy and workplaces safe during the Year 2020, awarded by the British Safety Council
- Awarded at the CII-Southern Region EHS Excellence Awards 2020 Edition
- Received at the CII-Southern Region EHS Excellence Awards 2020 Edition
- Awarded to our R&D Laboratory in Bengaluru, at the CII-Southern Region EHS Excellence Awards 2020 Edition
- Our R&D Laboratory at Mallapur places third in the Manufacturing Process - Services category at the CII-Southern Region EHS Excellence Awards 2020 Edition
- Awarded to our R&D Laboratory at Mallapur, at the CII-Southern Region EHS Excellence Awards 2020 Edition
- Received at the 30th Inflection Conference organized by Alden Global Value Advisors
- Awarded to Manufacturing Unit-I and R&D Laboratories at Nacharam, Hyderabad
- Received in recognition of exemplary work during the pandemic, from the National HR Development Network
- Awarded by Employer Branding Institute - India
- The first biopharmaceutical services company out of India to become a Great Place To Work-Certified™ organization for 2020-21
- Received in the Biopharma category, at the 10th Inflection Conference & Awards
- Received at the Logistics & Supply Chain Tech Innovation Summit & Awards
- Received at the Logistics & Supply Chain Tech Innovation Summit & Awards
- Recognized for the third consecutive year, by Employer Branding Institute - India
- Received at the 13th Employer Branding Awards, from Employer Branding Institute - India
- Received for the second consecutive year, at the 13th Employer Branding Awards, from Employer Branding Institute - India
- Received for demonstrating Best-in-Class Environmental, Health and Safety Practices, at the CII-Southern Region EHS Excellence Awards
- Received for delivery of a candidate that achieved first-in-human dose milestone, from GlaxoSmithKline
- Received 2nd Runner-Up at Yes Bank’s National Capital Awards
- Awarded for Excellence in EHS Practices, at the CII-Southern Region EHS Excellence Awards 2017 Edition
- Received in the Process Industry – Pharmaceuticals category, at the CII-Southern Region EHS Excellence Awards 2017 Edition
- Received from CFI.co, a 170-year old UK-based publication
- Received in the Best Environment Friendly Project category at the World CSR Congress
- Received by Mr D S Brar for his contribution to the Pharmaceutical and Life Sciences Industry, at BioAsia 2011
- Awarded in the Indian Contract Research Service Market category, by Frost & Sullivan
- Received for Best New Partnership with Wyeth, at the European Outsourcing Awards 2009
- Recognized by Business Today
- Awarded at Proximare’s IBC Conference
Leaders
- Krishna S Ethiraj, PhD
- Manni Kantipudi
- Amar Karandikar
- Srinivas Reddy Mamidi
- Davinder Singh Brar
- Swapnil Wadhwa
- Suveer Shrivastava
- G V Keshav Reddy
- Rajat Sood
- Robert R Ruffolo, PhD
- Ajay Srivastava
- Anita Ramachandran
- Manni Kantipudi
- Subodh Deshmukh
- Ashu Tandon
- Sachin Dharap
- Suresh Anubolu
- Somesh Sharma, PhD
- Shanavas Alikunju, PhD
- Malavika Ghosh, PhD
- Pratima Srivastava, PhD
- Girish Joshi, PhD
- D Vijaya Bharathi, PhD
- Vaibhav Sihorkar
- Naveen Kumar Annam
- Vikas Katial
- Ramesh Gambhir
- Shivaji Dashrath Jadhav
- Chandan P Shirbhayye
- Dr. Ravindrakumar Manikrao Kshirsagar
- Chassidy Hall
- Keshav Vasanthavada
- Takahiro Kuno
Publications
- Galeterone and the Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-resistant Prostate Cancer Preclinical Models in vitro and in vivo
- Oxidative Degradation Profile Studies of Tavaborole by a Validated Stability Indicating RP-UPLC method: Isolation and Characterization of Novel Degradant using 2D-NMR and HRMS
- Mass Spectrometry as a Workhorse for Preclinical Drug Discovery: Special Emphasis on Drug Metabolism and Pharmacokinetics
- Investigation of the Inhibition of Eight Major Human Cytochrome P450 Isozymes by a Probe Substrate Cocktail In Vitro with Emphasis on CYP2E1
- Oral Pharmacokinetics of Sildenafil in the Presence of CYP3A4-Inducer and -Inhibitor using Cannulated and Non-Cannulated Male Swiss Albino Mice
- Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation In Drug Discovery and Development
- Design, Synthesis and Anticancer Evaluation of Spiro[Cyclohexane-1,1’-Indene]-2,5-Diene Analogues
- An Efficient Method for the Preparation of N -Formamides using Propylphosphonic Anhydride (T3P)
- An Efficient Microwave-Assisted Propylphosphonic Anhydride (T3P®)-Mediated One-Pot Chromone Synthesis via Enaminones
- An Efficient One-Pot Green Approach for the Synthesis of A-aminonitriles with Alsba-15 as Nano Tubular Catalytic Reactor
- The Disappearing Director: The Case of Directed N-Arylation via a Removable Hydroxyl Group
- Highly Efficient Metal-Free One-Pot Synthesis of α- aminophosphonates through Reduction followed by Kabachnik–Fields Reaction Using Three-Component System
- First Total Synthesis of Medicinally Important 3,4,7-Trimethoxy-9, 10-Dihydrophenanthrene-1,5-Diol
- Preclinical Pharmacokinetics, Antitumor Activity and Single Ascending Dose Tolerability of GBO-006 Nanosuspension, A Selective Polo-Like Kinase 2 (PLK2) Inhibitor
- "One-Pot" Selective Synthesis of 3,4-Disubstituted Pyrroles and Benzo[F]Indole-4,9-Diones from 1,3-Indanedione, Aromatic Aldehydes and Tosmic
- Synthesis of Novel Fused Chromone–Pyrimidine Hybrids and 2,4,5-Trisubstituted Pyrimidine Derivatives via ANRORC Rearrangement
- A Novel Synthesis of Chromone Based Unnatural α-Amino Acid Derivatives
- One-Pot Synthesis of 7-chloro-2-arylthieno[3,2-b]pyridin-3-ols and their Derivatization to the Corresponding Arylamino, Arylthio, and Aryloxy
- Pd-PEPPSI-Ipentcl: A New Highly Efficient Ligand-Free and Recyclable Catalyst System for the Synthesis Of 2-Substituted Indoles via Domino Copper-Free Sonogashira Coupling/Cyclization
- First Total Synthesis of a Cytotoxic Derivative of the Natural Product Aaptamine
- Synthesis of Spiroindene-1,3-Dione Isothiazolines via a Cascade Michael/1,3-Dipolar Cycloaddition Reaction of 1,3,4-Oxathiazol-2-one and 2-Arylidene-1,3-Indandiones
- Cytochrome P450 Enzymes, Drug Transporters and their Role in Pharmacokinetic Drug-Drug Interactions of Xenobiotics: A Comprehensive Review
- Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation
- Drug Metabolism – Metabolite Identification Using Advance LC-MS/MS System
- Design, Synthesis and Biological Evaluation of Diaziridinyl Quinone Isoxazole Hybrids
- Design and Synthesis of Diaziridinyl Quinone Thiadiazole Hybrids via Nitrile Sulfide Cycloaddition Reaction as a Key Step
- An Efficient Method for the Preparation of N-Formyl-Imide via Amidine using Propylphosphonic Anhydride (T3P®)
- I2–DMSO Promoted Metal Free Oxidative Cyclization for the Synthesis of Substituted Indoles and Pyrroles
- A New Metabolite of Paricalcitol: Stereoselective Synthesis of (22Z)-Isomer of 1a, 25-Dihydroxy-19-Norvitamin D2
- An Efficient Synthesis of 8-Substituted Odoratine Derivatives by the Suzuki Coupling Reaction
- Preclinical Formulation for the Pharmacokinetics and Efficacy of GBO-006, a Selective Polo Like Kinase 2 (PLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer
- Design, Synthesis, and Evaluation of (2S, 4R)-Ketoconazole Sulfonamide Analogs as Potential Treatments for Metabolic Syndrome
- Synthesis of 6-Oxopyrimidin-1(6H)-Yl Benzamide Derivatives and Evaluation of their Antibacterial and Cytotoxic Activity
- Design, Synthesis and Biological Evaluation of Diaziridinyl Quinone Isoxazole Hybrids
- Synthesis of New Kojic Acid Based Unnatural α-Amino Acid Derivatives.
- Pd Catalyzed C–N Bond Forming Reactions of 6-Bromo-2-Cyclopropyl-3-(Pyridyl-3-ylmethyl)-4-quinazolin-(3H)-one at Room Temperature
- Facile and Short Synthesis of (+) 1-Hydroxy Indolizidine and (+) Coniceine from Picolinic Acid Ethyl Ester via Cross Claisen Condensation
- Synthesis, In Vitro Anticancer And Antimycobacterial Evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino Derivatives
- Mild and General Access to Diverse 1H-Benzotriazoles via Diboron-Mediated N–OH Deoxygenation, and Pd-Catalyzed C–C and C–N Bond Formation
- Design, Synthesis, And Biological Evaluation Of Quinazoline Derivatives As α-glucosidase Inhibitors
- Breaking the Sensitivity Limitations of Cytochrome P450 Oxidation Product: Dansyl Chloride Derivatization Of 4-OH Mephenytoin, a CYP2C19 Metabolite and its Application to In Vitro CYP Inhibition Assay
- Liquid Chromatography/Tandem Mass Spectrometry Method for Quantitative Estimation of Solutol HS15 and its Applications
- Development and Application of PI3K Assays for Novel Drug Discovery
- Novel Imidazoline Antimicrobial Scaffold That Inhibits DNA Replication with Activity against Mycobacteria and Drug Resistant Gram-Positive Cocci
- Design, Synthesis and Biological Evaluation of Novel Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors
- Design and Synthesis of Novel Isoxazole Tethered Quinone-Amino Acid Hybrids
- First Total synthesis of (-)-Auranomide C and its Derivatives
- Synthesis, Anticonvulsant, Sedative and Anxiolytic Activities of Novel Annulated Pyrrolo[1,4]benzodiazepines
- A Convenient and Efficient Synthesis of 2-(Het)arylthieno[3,2-b]pyridine-7(4H)-ones and 2,3-Di(het)arylthieno[3,2-b]pyridine-7(4H)-ones
- Pyrrolidine and Piperidine Based Chiral Spiro and Fused Scaffolds via Build/Couple/Pair Approach
- Effect of Milnacipran and Atorvastatin Alone and in Combination in Rodent Model of Inflammatory Pain
- Optimization of Bupivacaine Induced Subarachnoid Block by Clonidine: Effect of Different Doses of Oral Clonidine
- A Randomized Double-Blinded Dose Response Study of the Fentanyl with Hyperbaric Ropivacaine in Caesarean Section
- Atorvastatin Potentiates the Anti-Nociceptive Effect of Milnacipran in Carrageenan-Induced Inflammatory Pain Model in Rats
- Development of Phosphocellulose Paper-Based Screening of Inhibitors of Lipid Kinases: Case Study with PI3K?
- ATP Competition of PI3K Inhibitors using Phosphocellulose Paper Approach
- Liquid Chromatography/Tandem Mass Spectrometry Method for Estimation of Cholic Acid in Rat Plasma, Urine and its Application
- Identification and Reduction of Matrix Effects caused by Cremophor EL In Bioanalysis using Liquid Chromatography/Tandem Mass Spectrometry
- Liquid Chromatography/Tandem Mass Spectrometry Method for Quantitative Estimation of Polyethyleneglycol 400 and its Applications
- Synthesis of Privileged Scaffolds by Using Diversity-Oriented Synthesis
- Facile Total Synthesis Of Gymnoconjugatin A and B
- A Reagent Based DOS Strategy via Evans Chiral Auxiliary: Highly Stereoselective Michael Reaction Towards Optically Active Quinolizidinones, Piperidinones And Pyrrolidinones
- Diversity Oriented Synthesis of Macrocyclic Diaryl Ethers by Dötz Benzannulation
- A Novel One-Pot Synthesis of 7-methoxy-2-arylthieno – [3,2-b] pyridine-3-ols in Domino Fashion
- Concise Total Synthesis of (-)-Erinapyrone B from D-(+)-Malic Acid
- Development of α-Glucosidase Inhibitors by Room Temperature C–C Cross Couplings of Quinazolinones
- Ethyl-1-Imidazole Carbamate (EImC) as a Carbonylating Agent: Efficient Synthesis of Oxazolidin-2-ones from Amino Alcohols
- Identification and Reduction of Matrix Effects caused by Solutol HS15 in Bioanalysis using Liquid Chromatography/Tandem Mass Spectrometry
- Liquid Chromatography/Tandem Mass Spectrophotometry Method for Quantitation of Cremophor EL and its Applications
- Bioanalytical Method Development and Validation for Estimation of Duloxetine Hydrochloride in Human Plasma using LC-MS/MS
- Determination of Cremophor EL in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study
- Identification and Reduction of Matrix Effects caused by Polyethyleneglycol 400 in Bioanalysis using Liquid Chromatography/Tandem Mass Spectrometry
- Virtual and Experimental High-Throughput Screening (HTS) in Search of Novel Inosine 5′-Monophosphate Dehydrogenase II (IMPDH II) Inhibitors
- An Efficient One-Step Chemoselective Reduction of Alkyl Ketones over Aryl Ketones in ß-diketones using LiHMDS and Lithium Aluminium Hydride.
- An Efficient Method for the Preparation of Mono A-aryl Derivatives of Diethyl Cyanoacetate using Ethyl-1-Imidazole Carbamate (ElmC)
- Pd-Catalyzed Amination of 6-halo-2-cyclopropyl-3-(pyridyl-3-ylmethyl) quinazolin-4(3H)-one
- Synthesis of Novel Isoxazole-benzoquinone Hybrids via 1,3-dipolar Cycloaddition Reaction as Key Step
- Synthesis and Cytotoxicity Testing of New Amido-Substituted Triazolopyrrolo[2,1-c][1,4]benzodiazepine (PBDT) Derivatives
- C–C Cross-Coupling Reactions of O6-Alkyl-2-Haloinosine Derivatives and a One-Pot Cross-Coupling/O6-Deprotection Procedure
- Enantiospecific First Total Synthesis of 7a(S)-p-hydroxyphenopyrrozin
- Palladium Catalyzed Synthesis of Quinazolino [1,4] Benzodiazepine Alkaloids and Analogues
- Synthesis and Antibacterial Activity of 6-Substituted Anacardic Acid Derivatives
- Facile Two-Step Synthesis of Crispine A and Harmicine by Cyclopropylimine Rearrangement
- Diversity-Oriented Synthesis of Amino Acids using Chiral Enolates
- Enantioselective Synthesis of Spirooxoindoles via Chiral Auxiliary (Bicyclic Lactam) Controlled SNAr Reactions
- Synthesis and Antibacterial Activity of Anacardic Acid Derivatives
- SPF32629A and SPF32629B: Enantioselective Synthesis, Determination of Absolute Configuration, Cytotoxicity and Antibacterial Evaluation
- An Efficient Method for the Preparation of Mono A-Aryl Derivatives of Diethyl Malonate and Ethyl Cyanoacetate using Ethyl-1-Imidazole Carbamate(EImC)
- Azaindolines: Derisking the Indoline Structural Alert
- The First Total Synthesis of Potent Human Chymase Inhibitor SPF32629B via Regioselective Bromination and O-Acylation Strategy
- LC/MS/MS Method for the Simultaneous Estimation of Losartan Potassium and Irbesartan in Rat Plasma
- Structure-Based Design of 3-Aryl-6-amino-triazolo[4,3-b] pyridazine Inhibitors of Pim-1 Kinase
- Analytical Study of Charge Transfer Complexation of Rabeprazole with 2,3-Dichloro-5,6-Dicyano-1,4-Benzoquinone
- The First Total Synthesis of Novel Human Chymase Inhibitor
- The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry
Resources
- Therapeutic Impact of an ALK5 Inhibitor Across Multiple Preclinical Fibrosis Models
- Combat Nitrosamine Challenges with Comprehensive Analytical Solutions
- Revolutionizing new drug discovery- Harnessing AI ML Tools
- Your partner for timely, accurate and high-quality preclinical efficacy studies
- PROTACs: Breaking Boundaries in Drug Discovery
- Enhancing mAb platform process using Membrane chromatography (Affinity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines
- In vitro phototoxicity validation study
- Decoding the Conformational Plasticity of Ternary Complexes for Protacs’ Differential Activity
- Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer
- Navigating Recombinant Protein Production– Leveraging Aragen’s Multifaceted Expression Systems
- Gene to GMP: First-in-human in 8 Months with Optimized Cost
- Comparative Analysis: Responses to Immunotherapy
- Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis
- Modalities for Mechanistic Exploration in Agrochemical Solutions
- Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model
- Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
- Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models
- Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models
- Flow Chemistry vs. Batch Processes
- A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform
- A Highly Reproducible In Vivo Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis
- Preclinical Models of Immune oncology for CART-cell Therapeutics Development
- Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models
- Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models
- Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model
- Pharmacokinetic Strategies in CNS Drug Discovery
- Targeted Protein Degradation in Inflammation and Cancer Therapy
- Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions
- Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules
- Accelerating Vaccines to Clinical Trials — A Toolkit for Efficacy, Safety and Bioanalytical Studies
- Upstream Process Development for Better Yield and Product Quality
- The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development
- Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform
- Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models
- Development of Covalent Drugs with New Emerging Technologies
- Accelerating Biologics Development to Medicines: Key Drivers of Success
- Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification
- A Preclinical Efficacy Study using Diet induced Obesity Mice Model
- Solutions for Mitigating Challenges in Recombinant Protein Production
- Propelling Glioblastoma Research: Aragen Bioscience's Orthotopic Model Solutions
- In vitro/In vivo Correlation of Permeability
- Blood Brain Permeability and CNS Bioavailability
- Column Head Loading in SFC
- Phenotypic Characterization of Bleomycin-Induced Pulmonary Fibrosis Model
- Reliable and Reproducible Preclinical Rodent Models of MAS
- Paclitaxel-induced Peripheral Neuropathic Pain Model Developed at Aragen
- Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide
- Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability
- Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics
- Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels
- Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors
- Comprehensive Services for Immersive Corrosion Testing of Metals and Alloys Across a Wide Spectrum of Test Subjects
- Aragen Cell Line Development Solutions for Biologics CHO CLD Platforms
- Comprehensive Solutions for Animal Health Biologics
- Comprehensive In-Vitro Microbial Kill Rate Studies for screening antimicrobial agents
- Clinically relevant preclinical model of CFA-Induced inflammatory pain
- Exploring Molecular Interactions Through Surface Plasmon Resonance
- Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics
- Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches
- Genetic and Alternative Toxicity Testing for Compound Screening, Derisking and Selection
- Flow Chemistry
- Oligonucleotides
- Phosphonamidite
- Specialized Services in Custom Peptide Synthesis (Solution Phase)
- Comprehensive DoE capabilities for Synthesis, Process Development and Manufacturing of Novel Chemical Entities (NCE’s)
- Comprehensive GLP regulated Ecotoxicology Services
- A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance
- A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells
- Comprehensive and Regulated “Developmental and Reproduction Toxicology (DART)” studies
- Preclinical Safety Evaluation and Clinical Bioanalysis Services for Vaccines
- Intox Safety Assessment
- Nonclinical Safety Assessment of New Biological Entities (NBEs)
- A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance
- Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data
- Process Safety, Dust Explosion Testing Capabilities
- Material Science
- Aragen Overview
- Comprehensive Preclinical Development Program for a COVID mRNA Vaccine
- Nonclinical Safety Assessment of New Chemical Entities (NCE)
- Aragen protein science solutions: Industry leading upstream and downstream capabilities
- Your Partner for Chemocatalysis Solutions
- Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
- Biocatalysis Solutions
- Flow Chemistry
- Analytical Solutions
- Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen
- Targeted Protein Degradation Solutions
- Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences
- Aragen’s quantitative proteomics sampling capabilities: Accurate and Reproducible Workflows
- Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein
- Experimental pain models at Aragen Life Sciences - Spinal Nerve Ligation (SNL) Model of Neuropathic Pain
- Pharmacokinetics (PK)/ Pharmacodynamics (PD) and Mechanistics solutions in Ellegaard Göttingen Minipigs
- Comprehensive Characterization of Biologics
- Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.
- Automation to miniaturize In vitro assays to achieve superior and cost-efficient results
- Targeted Protein Degradation
- Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice
- An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)
- Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics
- Aragen’s Preclinical Oncology Capabilities
- Preclinical Evaluation of new Antifibrotics in IPF Rodent Models
- Industry Leading Hybridoma Technique for Accelerated Antibody Discovery
- Covalent Drugs – Advantages, Challenges, And Opportunities
- Mitigating CMC issues through Aragen’s holistic approach to developability assessment
- Aragen’s Preclinical Oncology Capabilities - Tumor Imaging
- Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models
- Aragen’s Oncology solutions: Accelerate your cancer therapeutics development
- Pharmacokinetic (PK) solutions in large animals
- RSV Challenge Model for anti-RSV therapy
- Cell Line Development at Aragen: Research cell banks in 5 months
- Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models
- DSS-induced IBD Mouse Model for preclinical drug screening
- Formulation Solutions
- Discovery Biology Solutions
- Cell Line Development at Aragen; Accelerating speed to IND
- ADME – DMPK Solutions
- Extractables and Leachables Solutions
- In Vitro Pharmacology Solutions
- In Vivo Pharmacology Solutions
- Nitrosamine Impurity Detection and Quantification
- TOXVIT - Aragen In Vitro Toxicology Solutions
- ICP-MS
- Protein Analytics Solutions
- Peptide Chemistry Solutions
- API and Intermediates
- Integrated Drug Discovery Solutions
- Discovery Chemistry Solutions
- Developability and Analytics Solutions
- Contract Manufacturing Solutions
- Integrated Cell Line Development Solutions
- Small Molecule Process R&D and Manufacturing Solutions
- Enabling Formulation Development for Toxicology Studies for a New Chemical Entity
- Physical Form Selection of a Small Molecule
- Amylin Liver NASH (AMLN)
Testimonials
- Chris Nasveschuk
- Dr. Kathleen Shelton
- Rajat Sood
- Alan Joslyn, Ph.D.
- Timothy Compton
- Dr Andrew Growth
- Adar Poonawalla
Training Calendar
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 20203
- October 2023
- September 2023
- August 2023
- July 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
Brochures
- Combat Nitrosamine Challenges with Comprehensive Analytical Solutions
- Navigating Recombinant Protein Production– Leveraging Aragen’s Multifaceted Expression Systems
- Modalities for Mechanistic Exploration in Agrochemical Solutions
- Your Partner to Fast-Track Trace Metals Analysis
- Extractables and Leachables Solutions
- Formulation Development Solutions
- Nonclinical Safety Assessment of New Chemical Entities (NCE) IND in 9 Months
- Comprehensive Solutions for Animal Health Biologics
- Analytical Solutions Laboratory
- Flow Chemistry Solutions
- Your Partner for Biocatalysis Solutions
- Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
- Your Partner for Chemocatalysis Solutions
- Process Safety, Dust Explosion Testing Capabilities
- Targeted Protein Degradation Solutions
- Preclinical Evaluation of New Antifibrotics in IPF Rodent Models
- Aragen’s Preclinical Oncology Capabilities
- Comprehensive Characterization of Biologics
- Comprehensive Phosphoramidite chemistry capabilities for the synthesis of oligonucleotides
- Genetic and Alternative Toxicity Testing for Compound Screening, Derisking and Selection
- Your Science. Our Solutions. Together Ahead
- Material Science Solutions
- Intox Safety Assessment
- Comprehensive DoE capabilities for Synthesis, Process Development and Manufacturing of Novel Chemical Entities (NCE's)
- Accelerating Oligonucleotides Discovery and Development Programs
- Comprehensive In-Vitro Microbial Kill Rate Studies for screening antimicrobial agents
- Comprehensive Services for Immersive Corrosion Testing of Metals and Alloys Across a Wide Spectrum of Test Subjects
- Case study - Flow Chemistry experiments of highly hazardous Butyl Lithium Reactions
- Nonclinical Safety Assessment of New Biological Entities (NBEs)
- Paclitaxel-induced Peripheral Neuropathic Pain Model Developed at Aragen
- Rigorous and Comprehensive Analytics to Support Biologics Discovery and Development
- Specialized Services in Custom Peptide Synthesis (Solution Phase)
- Small Molecule Process R&D and Manufacturing
- Aragen Cell Line Development and Process Development Solutions for Biologics CHO CLD platforms
- Biosimilar Development at Aragen
- Preclinical Safety Evaluation and Clinical Bioanalysis Services for Vaccines
- Comprehensive GLP-regulated Ecotoxicology Services
- Comprehensive and GLP “Developmental and Reproductive Toxicology (DART)” studies
- Peptide Technology Platform
- Discovery Chemistry Solutions
- Pharmacokinetic (PK) solutions in large animals
- Integrated DMPK services for lead optimization and IND filing
- Integrated cell line development solutions
- Aragen protein science solutions: Industry leading upstream and downstream capabilities
Articles
- Aragen’s Solutions for Mitigating Challenges in Recombinant Protein Production
- Propelling Glioblastoma Research: Aragen Bioscience's Orthotopic Model Solutions
- Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics
- Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences
- Exploring Molecular Interactions Through Surface Plasmon Resonance
- Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice
- Targeted Protein Degradation: Challenges and Opportunities
- Automation to miniaturize In vitro assays to achieve superior and cost-efficient results
- Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.
- Experimental pain models at Aragen Life Sciences - Spinal Nerve Ligation (SNL) Model of Neuropathic Pain
- Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen
- Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models
- DSS-induced IBD Mouse Model for preclinical drug screening
- Covalent Drugs – Advantages, Challenges, And Opportunities
- Preclinical Model of Post- Incisional Pain for Efficacy Testing of Novel Therapeutics
- Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels
- Clinically relevant preclinical model of CFA-Induced inflammatory pain
- Cell Line Development: Reducing Timeline to IND Submission
- Mitigating CMC issues through Aragen’s holistic approach to developability assessment
- Industry Leading Hybridoma Technique for Accelerated Antibody Discovery
- Aragen’s Preclinical Oncology Capabilities - Tumor Imaging
- Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics
- Key Challenges in Cell Line Development: Aragen’s Comprehensive solutions
- Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data
- RSV Challenge Model for anti-RSV therapy
- Cell Line Development at Aragen: Research cell banks in 5 months
- A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells
Case Studies
- Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis
- Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model
- Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification
- A Pre-clinical Study for Diet-induced Obesity
- Case Study - Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein
- Case Study - Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches
- Case Study - Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors
- Case Study - Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability
- Case Study - A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance
- Case Study - A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance
- An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)
- Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide.
Videos
- Tox Services - Capabilities and Infrastructure
- Discovery Chemistry Facilities
- Manufacturing Facility at Visakhapatnam, India
- Discovery Biology R&D Facilities
- Vivarium Facility at Bangalore, India
- Formulations Manufacturing Facility
- Manufacturing Unit at Hyderabad, India
- Analytical Research Facility
- Aragen's Kilo Lab
Leader Categories
- Discovery Solutions
- Development and Manufacturing Solutions
- Biologics Solutions
- Business Enabling Functions
- Business Development
- Board of Directors
- Management Team
- Senior Leadership
